Skye Bioscience to Participate in Upcoming Investment Conferences

About this update from Skye Bioscience, Inc.

San Diego, California--(Newsfile Corp. - November 24, 2025) - Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will participate in the following upcoming investment conferences: Available webcasts will be accessible on Skye's website . About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of potential first-in-class therapeutics with potential clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial ( ClinicalTrials.gov: NCT06577090 ) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com . Connect with us on X and LinkedIn . CONTACTS Investor & Media Relations [email protected] (858) 410-0266 LifeSci Advisors, Mike Moyer [email protected] (617) 308-4306 To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275680

View stock analysis, news, and events for Skye Bioscience, Inc.